Newark, Del., about 50 patients have already enrolled in the study, and the NSABP is registering 400 patient-accrual sites throughout the U.S.
The patients being studied have a 50% risk of colon cancer relapse. As Boman explained, "We felt that in a chemopreventive study we needed to look at a high-risk population where the benefi t -risk ratio for 
Promise for Reducing Polyps
To follow up on the NEJM study, Ali Siddiqui, M.D ., and colleagues at Dallas Veterans Affairs Medical Center looked at the outcomes of colon cancer patients who were long-term statin users.
"We were trying to elicit whether the statins were actually working at the stage of reducing the progression of polyps to advanced polyps," said Siddiqui, now a gastroenterologist at the Thomas Jefferson Medical School in Philadelphia.
Among the 2,626 patients who had polyps removed at colonoscopy, 35% of those who reported ongoing statin usage developed new polyps, compared to 51% of nonusers. Furthermore, patients on statins developed smaller and less advanced polyps than nonusers. Despite these encouraging results, which the journal Digestion published in 2009, Siddiqui says not enough clinical evidence exists to consider statins a chemopreventive therapy for colorectal cancer.
"Right now, it's diffi cult for me to tell patients to go on statins [for this indication]," said Siddiqui. "Our data support it, but there are studies that do not support the use of statins."
Molecular Biology of Statins
Other studies are exploring the molecular biology regarding how statins may reduce colorectal cancer risk. The class of drugs that includes statins are 3-hydroxy-3-methylglutaryl -coenzyme A reductase (HMGCR) inhibitors. These compounds inhibit a key enzyme in the cholesterol-synthesis pathway, thereby reducing serum cholesterol levels. This same pathway also participates in the synthesis of molecules that act as growth factors and are involved in cell survival pathways. Those dual -and confl icting -roles may help explain the mixed results of epidemiological studies on statins ' effect on cancer cells.
A recent study on statins ' effect on colon cancer cell lines looked at whether statins boost levels of bone morphogenetic protein, which inhibits colon cancer growth. The researchers at the Academic Medical Center in Amsterdam used mouse xenograft models of several well-characterized colon cancer cell lines. Their fi ndings, published in the journal Gastroen terology in 2007, suggest that some cancer cells are sensitive to statins, whereas other cancer cell types resist statins ' effects. Furthermore, although statins boosted levels of bone morphogenetic protein and inhibited growth of statin-sensitive colon cancer cells, statins actually increased cell growth in statin-resistant cell lines.
Another recent study uncovered a genetic variation in the HMGCR gene that may partially explain lack of benefi t from statin use, at least in some individuals, either as a lipid-lowering agent or as chemopreventive therapy for colon cancer. Using data and blood samples from the same database reported in the 2005 NEJM study, a multi-institutional team of scientists studied genetic variation in 40 genes involved in cholesterol synthesis in 2,138 colon cancer case patients and 2,049 matched control subjects. Using statistical methods, the research team analyzed whether any genetic variants were associated with long-term statin use and later development of colon cancer. The scientists found that a single genetic variant, called A/A, was associated with a lower risk of colon cancer, as well as lower lowdensity lipoprotein levels among all case patients and control subjects. Individuals with the alternate T/T genotype who took statins had higher low-density lipoprotein levels than those with the A/A variant and had 
